• Investing Insights & Exclusive Offers → Get Our FREE “Market Brief”
    Sign-up for our free weekly newsletter. Get unparalleled investing insights and exclusive Summer Sale discounts on Hedgeye research.

    Disclaimer: By joining our email marketing list you agree to receive marketing emails from Hedgeye. You may unsubscribe at any time by clicking the unsubscribe link in one of the emails. Use of Hedgeye and any other products available through hedgeye.com are subject to our Terms Of Service and Privacy Policy

Watch the replay below

Healthcare analyst Tom Tobin and Health Policy analyst Emily Evans review their best stock ideas, major healthcare themes and more. They also take questions from the live viewer audience after their prepared remarks. 

TOPICS WILL INCLUDE:

  • DXCM |  A new look at our medical claims data may yield a more accurate look into the market for continuous glucose monitoring. We spoke to two endocrinologists we identified through our medical claims data because they were at group practices that submit a high number of claims for cgm “data interpretation.” The anecdotes tell the same story we heard last year and support the short case, but a new analysis of the data looks more accurate.
  • HCA |  Our algorithm method proved accurate in calling the upside to HCA’s 4Q19 same facility adjusted admissions growth. If the method holds up we should see upside at MD and an inline number at THC. 
  • ILMN | We’ve assembled a chart book for genetic testing volume trends across a number of key labs, both public and private. While Illumina beat and maintained guidance for 2020, they back end loaded the year resulting in more doubt and falling consensus estimates. The market looks good for ILMN, both academic and commercial labs,  so we are sticking with the long. 

CLICK HERE to access the associated slides